Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) EBITDA (2022 - 2026)

Lexeo Therapeutics' EBITDA history spans 2 years, with the latest figure at -$15.0 million for Q4 2023.

  • On a quarterly basis, EBITDA rose 1.47% to -$15.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$68.5 million, a N/A change, with the full-year FY2025 number at -$99.7 million, down 1.25% from a year prior.
  • EBITDA hit -$15.0 million in Q4 2023 for Lexeo Therapeutics, up from -$20.3 million in the prior quarter.
  • Over the last five years, EBITDA for LXEO hit a ceiling of -$14.0 million in Q2 2023 and a floor of -$20.3 million in Q3 2023.